GlassScriptPhysician profile
Louise A Leblanc
NPI 1679755425
$1,023.32
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $948 · 2022: $75.63.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $308.57 | 2021-2022 | |
| Esperion Therapeutics, INC. | $121.62 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $106.72 | 2021 | |
| Emd Serono, INC. | $62.32 | 2021 | |
| Amgen INC. | $52.43 | 2021 | |
| Janssen Pharmaceuticals, INC | $48.91 | 2021 | |
| Amarin Pharma, INC. | $37.93 | 2021 | |
| Daiichi Sankyo INC. | $36.75 | 2021 | |
| Genzyme Corporation | $35.41 | 2021 | |
| Abbvie INC. | $32.17 | 2021 | |
| Lilly USA, LLC | $29.60 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.51 | 2021 | |
| Celgene Corporation | $23.47 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.35 | 2021 | |
| Vyera Pharmaceuticals, LLC | $22.65 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Clarus Therapeutics INC. | $22.18 | 2021 | |
| Pfizer INC. | $20.52 | 2021 | |
| Ibsa Pharma INC. | $11.21 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Louise Leblanc listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.